Propagermanium

Drug Profile

Propagermanium

Alternative Names: Proxigermanium; Serocion; SK 818

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanwa Kagaku Kenkyusho
  • Developer Astellas Pharma; Sanwa Kagaku Kenkyusho
  • Class Antivirals; Organometallic compounds; Small molecules
  • Mechanism of Action Immunomodulators; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis B
  • No development reported Crohn's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Crohn's-disease in Japan
  • 01 Mar 2012 Preclinical trials in Crohn's disease in Japan (unspecified route)
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top